- Customers will start receiving shipments from July 10 with additional shipments through October
to healthcare provider offices, pharmacies and other immunizers to
support fall immunization campaigns.
- Sanofi annual higher-dose influenza (flu) vaccinations have
been proven to help protect from flu and shown to better protect
from serious complications of flu such as pneumonia and cardiac
events when compared to standard dose vaccines in older
adults.
BRIDGEWATER, N.J., July 10,
2024 /PRNewswire/ -- Sanofi today started shipping
its first influenza (flu) vaccines across the U.S. in preparation
for the 2024/25 flu season. Following this first shipment,
additional shipments of the full Sanofi flu vaccine
portfolio will continue through October to healthcare provider
offices, pharmacies and other immunizers to support fall
immunization campaigns. With over 125 years of heritage in helping
protect global public health, Sanofi is a world leader in
vaccines, helping to vaccinate more than 500 million people
annually.
Thomas Grenier
Head of
Vaccines, North America,
Sanofi
"Today, we began shipping flu vaccines for the upcoming season,
a moment that underscores our long-standing commitment to providing
global protection against disease. Getting a flu shot is imperative
to not only help protect against flu infection, but also to help
reduce the risks of its potentially severe complications, which can
lead to hospitalizations, especially in those most vulnerable.
Sanofi understands what these populations need out of their flu
shots and works tirelessly from start to finish to provide proven
and specific solutions."
All flu vaccines provided by Sanofi to the US market are
trivalent, meaning they offer protection against the current three
strains of influenza (two influenza A strains and one influenza B
strain). These strains were selected based on a collaborative
review of influenza surveillance by the U.S. Food and Drug
Administration (FDA), World Health Organization (WHO), the Centers
for Disease Control and Prevention (CDC), among other public health
experts, as the strains most likely to cause illness in the
upcoming flu season.
Annual flu vaccination is one of the best ways to help protect
against flu and its complications. Public health authorities
worldwide reiterate their recommendations for eligible people to be
vaccinated every year.
As one of the largest providers of influenza vaccines to
the United States with a range of
options, Sanofi meets immunization needs across the lifespan,
from children as young as six months of age through adults 65 years
of age and older. This year's 2024/25 U.S. influenza season
portfolio includes Fluzone High-Dose (Influenza Vaccine), Flublok
(Influenza Vaccine) and Fluzone (Influenza Vaccine).
Indication and Important Safety Information
for Fluzone® High-Dose (Influenza Vaccine),
Flublok® (Influenza Vaccine) and Fluzone ®
(Influenza Vaccine)
What are Fluzone® (Influenza Vaccine),
Flublok® (Influenza Vaccine), and Fluzone®
High-Dose (Influenza Vaccine)?
Fluzone, Flublok, and Fluzone High-Dose are vaccines indicated
for the prevention of disease caused by influenza A and B strains
contained in the vaccine. Fluzone is given to people 6 months of
age and older. Flublok is given to people 18 years of age and
older. Fluzone High-Dose is given to people 65 years of age and
older.
IMPORTANT SAFETY INFORMATION FOR FLUZONE®
(INFLUENZA VACCINE), FLUBLOK® (INFLUENZA VACCINE), AND
FLUZONE® HIGH-DOSE (INFLUENZA VACCINE)
Fluzone, Flublok, or Fluzone High-Dose should not be given to
anyone who has had a severe allergic reaction to any component of
the vaccine (including eggs or egg products for Fluzone and Fluzone
High-Dose). In addition, Fluzone and Fluzone High-Dose should not
be given to anyone who has had a severe allergic reaction after a
previous dose of any influenza vaccine.
Tell your health care provider if you have ever
had Guillain-Barré syndrome (severe muscle weakness) after a
previous influenza vaccination.
If Fluzone, Flublok, or Fluzone High-Dose are given to people
with a compromised immune system, including those receiving
therapies that suppress the immune system, the immune response may
be lower than expected.
Vaccination with Fluzone, Flublok, or Fluzone High-Dose may
not protect all people who receive the vaccine.
Fainting has occurred following vaccination with Fluzone,
Flublok, and Fluzone High-Dose. Procedures should be in place to
avoid injury from fainting.
For Fluzone, in children 6 months through 8 years of age,
the most common side effects were pain or tenderness and redness
where you got the shot, irritability, drowsiness (6 month through
35 months), and muscle pain (3 years through 8 years). In adults 18
years through 64 years of age, the most common side effects were
pain where you got the shot, headache, and muscle pain. In adults
over 65 years of age, the most common side effects were pain where
you got the shot, headache, muscle pain, and general
discomfort.
For Flublok, in adults 18 through 64 years of age, the most
common side effects were pain where you got the shot, headache,
tiredness, and muscle pain. In adults 65 years of age and older,
the most common side effects were pain where you got the shot,
tiredness and headache.
For Fluzone High-Dose, in adults 65 years of age and older,
the most common side effects were pain where you got the shot,
muscle pain, tiredness, and headache.
For Fluzone, Flublok, and Fluzone High-Dose, other side
effects may occur.
For more information, talk to your healthcare professional and
refer to the full Prescribing and Patient information
for Flublok, Fluzone or Fluzone High-Dose.
About Sanofi
We are an innovative global healthcare company, driven by one
purpose: we chase the miracles of science to improve people's
lives. Our team, across the world, is dedicated to transforming the
practice of medicine by working to turn the impossible into the
possible. We provide potentially life-changing treatment options
and life-saving vaccine protection to millions of people globally,
while putting sustainability and social responsibility at the
center of our ambitions.
Sanofi is listed on EURONEXT: SAN and NASDAQ: SNY.
Contacts
Sandrine Guendoul | + 33 6
25 09 14 25 | sandrine.guendoul@sanofi.com
Evan Berland | +1 215
432 0234 | evan.berland@sanofi.com
Timothy Gilbert | + 1 516 521 2929
| timothy.gilbert@sanofi.com
Investor Relations
Thomas Kudsk Larsen |
+44 7545 513 693 | thomas.larsen@sanofi.com
Alizé Kaisserian | + 33 6 47 04 12 11
| alize.kaisserian@sanofi.com
Arnaud Delépine | + 33 6 73 69 36 93
| arnaud.delepine@sanofi.com
Felix Lauscher | + 1 908 612 7239
| felix.lauscher@sanofi.com
Keita Browne | + 1 781
249 1766 | keita.browne@sanofi.com
Nathalie Pham | + 33 7 85 93 30 17
| nathalie.pham@sanofi.com
Tarik Elgoutni| + 1 617 710 3587
| tarik.elgoutni@sanofi.com
Thibaud Châtelet | + 33 6 80 80 89 90 |
thibaud.chatelet@sanofi.com
Sanofi Forward-Looking Statements
This media
update contains forward-looking statements as defined in the
Private Securities Litigation Reform Act of 1995, as amended.
Forward-looking statements are statements that are not historical
facts. These statements include projections and estimates regarding
the marketing and other potential of the product, or regarding
potential future revenues from the product. Forward-looking
statements are generally identified by the words "expects",
"anticipates", "believes", "intends", "estimates", "plans" and
similar expressions. Although Sanofi's management believes that the
expectations reflected in such forward-looking statements are
reasonable, investors are cautioned that forward-looking
information and statements are subject to various risks and
uncertainties, many of which are difficult to predict and generally
beyond the control of Sanofi, that could cause actual results and
developments to differ materially from those expressed in, or
implied or projected by, the forward-looking information and
statements. These risks and uncertainties include among other
things, unexpected regulatory actions or delays, or government
regulation generally, that could affect the availability or
commercial potential of the product, the fact that product may not
be commercially successful, the uncertainties inherent in research
and development, including future clinical data and analysis of
existing clinical data relating to the product, including post
marketing, unexpected safety, quality or manufacturing issues,
competition in general, risks associated with intellectual property
and any related future litigation and the ultimate outcome of such
litigation, and volatile economic and market conditions, and the
impact that pandemics or other global crises may have on us, our
customers, suppliers, vendors, and other business partners, and the
financial condition of any one of them, as well as on our employees
and on the global economy as a whole. The risks and uncertainties
also include the uncertainties discussed or identified in the
public filings with the SEC and the AMF made by Sanofi, including
those listed under "Risk Factors" and "Cautionary Statement
Regarding Forward-Looking Statements" in Sanofi's annual report on
Form 20-F for the year ended December 31,
2023. Other than as required by applicable law, Sanofi does
not undertake any obligation to update or revise any
forward-looking information or statements.
MAT-US-2406730-v1.0-07/2024
View original
content:https://www.prnewswire.com/news-releases/sanofi-ships-us-influenza-vaccines-for-the-202425-season-302194084.html
SOURCE Sanofi